• Consensus Rating: Hold
  • Consensus Price Target: $104.83
  • Forecasted Upside: 379.57 %
  • Number of Analysts: 11
  • Breakdown:
  • 3 Sell Ratings
  • 6 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$21.86
▼ -0.7 (-3.10%)

This chart shows the closing price for IPSEY by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Ipsen Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for IPSEY and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for IPSEY

Analyst Price Target is $104.83
▲ +379.57% Upside Potential
This price target is based on 11 analysts offering 12 month price targets for Ipsen in the last 3 months. The average price target is $104.83, with a high forecast of $120.00 and a low forecast of $95.00. The average price target represents a 379.57% upside from the last price of $21.86.

This chart shows the closing price for IPSEY for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 11 investment analysts is to hold stock in Ipsen. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 5 hold ratings
  • 2 sell ratings
4/5/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 6 hold ratings
  • 2 sell ratings
7/4/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 5 hold ratings
  • 2 sell ratings
10/2/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 5 hold ratings
  • 2 sell ratings
12/31/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 6 hold ratings
  • 3 sell ratings
3/31/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 6 hold ratings
  • 3 sell ratings
6/29/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 6 hold ratings
  • 3 sell ratings
8/28/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 6 hold ratings
  • 3 sell ratings
9/27/2022

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 6 hold ratings
  • 3 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
8/26/2022CheuvreuxUpgradeHold ➝ Buy€110.00
8/2/2022Berenberg BankBoost TargetHold ➝ Hold€98.00 ➝ €102.00
8/1/2022Credit Suisse GroupBoost Target€95.00 ➝ €100.00
7/20/2022UBS GroupLower TargetNeutral ➝ Neutral€117.00 ➝ €102.00
4/29/2022Societe GeneraleBoost TargetBuy ➝ Buy€112.00 ➝ €120.00
4/27/2022Bryan, Garnier & CoDowngradeBuy ➝ Neutral
4/14/2022BarclaysBoost TargetUnderweight ➝ Underweight€88.00 ➝ €95.00
3/25/2022Credit Suisse GroupBoost TargetNeutral ➝ Neutral€87.00 ➝ €105.00
2/22/2022BarclaysBoost TargetUnderweight ➝ Underweight€78.00 ➝ €88.00
2/17/2022AlphaValueUpgradeReduce
1/11/2022UBS GroupUpgradeNeutral ➝ Buy
1/6/2022Societe GeneraleUpgradeHold ➝ Buy
1/4/2022JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral
11/24/2021Berenberg BankInitiated CoverageHold
11/5/2021Morgan StanleyDowngradeEqual Weight ➝ Underweight
10/22/2021Credit Suisse GroupReiterated RatingNeutral
10/19/2021Exane BNP ParibasInitiated CoverageNeutral
10/19/2021BarclaysDowngradeOverweight ➝ Underweight
10/11/2021JPMorgan Chase & Co.Reiterated RatingOverweight
10/7/2021Morgan StanleyReiterated RatingEqual Weight
8/16/2021Morgan StanleyReiterated RatingEqual Weight
8/3/2021Morgan StanleyReiterated RatingEqual Weight
8/2/2021Societe GeneraleReiterated RatingHold
7/30/2021Credit Suisse GroupReiterated RatingNeutral
6/29/2021Societe GeneraleReiterated RatingHold
6/14/2021Societe GeneraleDowngradeBuy ➝ Hold
5/28/2021BarclaysReiterated RatingOverweight
5/27/2021JPMorgan Chase & Co.Reiterated RatingOverweight
4/23/2021Societe GeneraleReiterated RatingBuy
4/20/2021Deutsche Bank AktiengesellschaftInitiated CoverageHold
2/16/2021BarclaysReiterated RatingOverweight
1/14/2021Societe GeneraleUpgradeHold ➝ Buy
12/8/2020Morgan StanleyDowngradeOverweight ➝ Equal Weight
12/4/2020Bank of AmericaDowngradeBuy ➝ Neutral
12/2/2020Bryan, Garnier & CoDowngradeBuy ➝ Neutral
10/26/2020BarclaysUpgradeEqual Weight ➝ Overweight
9/1/2020Morgan StanleyReiterated RatingOverweight
8/4/2020UBS GroupReiterated RatingBuy
8/3/2020Credit Suisse GroupReiterated RatingNeutral
7/31/2020BarclaysReiterated RatingEqual Weight
7/22/2020JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight
7/16/2020Societe GeneraleDowngradeBuy ➝ Hold
7/14/2020Morgan StanleyReiterated RatingOverweight
6/1/2020BarclaysReiterated RatingEqual Weight
6/1/2020Bank of AmericaUpgradeNeutral ➝ Buy
5/18/2020JPMorgan Chase & Co.UpgradeUnderweight ➝ Neutral
4/22/2020UBS GroupReiterated RatingBuy
4/20/2020BarclaysReiterated RatingEqual Weight
2/11/2020Credit Suisse GroupUpgradeUnderperform ➝ Neutral
1/9/2020Jefferies Financial GroupDowngradeBuy ➝ Hold
1/5/2020JPMorgan Chase & Co.DowngradeNeutral ➝ Underweight
12/9/2019BarclaysDowngradeOverweight ➝ Equal Weight
5/20/2019JPMorgan Chase & Co.UpgradeUnderweight ➝ Neutral
2/19/2019The Goldman Sachs GroupUpgradeSell ➝ Neutral
10/29/2018Credit Suisse GroupDowngradeNeutral ➝ Underperform
10/8/2018JPMorgan Chase & Co.DowngradeNeutral ➝ Underweight
9/28/2018The Goldman Sachs GroupInitiated CoverageSell
(Data available from 9/27/2017 forward)

News Sentiment Rating

0.00 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 3 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/1/2022
  • 3 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
3/31/2022
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/30/2022
  • 2 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
5/30/2022
  • 6 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
6/29/2022
  • 2 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
7/29/2022
  • 2 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 2 very negative mentions
8/28/2022
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/27/2022

Current Sentiment

  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Ipsen logo
Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, gastroenterology, cognitive disorders, and rare diseases. It offers Somatuline for neuroendocrine tumors and acromegaly; Decapeptyl for the treatment of advanced metastatic prostate cancer; Cabometyx for renal cell and second-line hepatocellular carcinoma; Onivyde for second-line metastatic pancreatic cancer; Dysport for motor muscular disorders and medical aesthetics; NutropinAq for growth failure in children due to growth hormone (GH) deficiency, turner syndrome, chronic renal failure, and GH deficiency in adults; and Increlex for growth failure in children and adolescents. The company also offers Smecta for chronic and acute diarrhea, and pain associated with functional bowel diseases; Forlax for constipation; Fortrans/Eziclen for bowel cleansing prior to endoscopy, X-ray examination, and colonic surgery; and Tanakan for cognitive disorders in adults, vertigo of vestibular origin and vestibular rehabilitation, and tinnitus. In addition, it provides Xermelo for the carcinoid syndrome; Cometriq for medullary thyroid cancer; Smebiocta/SmectaFlora Protect, a food supplement; SmectaGas, a medical device used in the symptomatic treatment of gas-related gastrointestinal disorders and relief of gas-related symptoms; and Etiasa for inflammatory bowel diseases. Further, the company offers other consumer healthcare products in the gastro-intestinal area, including Buscopan, Clin4000, Prontalgine, Suppositoria Glycerini, Mucothiol, Floractin, and Mucodyne. Ipsen S.A. has agreements with Debiopharm; Exelixis; Galderma; Blueprint Medicines; TerSera Therapeutics; Rhythm Pharmaceuticals; Teijin; Braintree Laboratories; Ethypharm; Schwabe; BAKX Therapeutics Inc.; and Exicure. The company was founded in 1929 and is headquartered in Boulogne-Billancourt, France.
Read More

Today's Range

Now: $21.86
Low: $21.86
High: $21.86

50 Day Range

MA: $24.24
Low: $21.86
High: $26.08

52 Week Range

Now: $21.86
Low: $21.17
High: $32.51

Volume

4,857 shs

Average Volume

1,396 shs

Market Capitalization

$7.33 billion

P/E Ratio

N/A

Dividend Yield

1.06%

Beta

1.04

Frequently Asked Questions

What sell-side analysts currently cover shares of Ipsen?

The following sell-side analysts have issued stock ratings on Ipsen in the last twelve months: AlphaValue, Barclays PLC, Berenberg Bank, Bryan, Garnier & Co, Cheuvreux, Credit Suisse Group AG, Exane BNP Paribas, JPMorgan Chase & Co., Morgan Stanley, Societe Generale, and UBS Group AG.
View the latest analyst ratings for IPSEY.

What is the current price target for Ipsen?

6 Wall Street analysts have set twelve-month price targets for Ipsen in the last year. Their average twelve-month price target is $104.83, suggesting a possible upside of 379.6%. Societe Generale has the highest price target set, predicting IPSEY will reach $120.00 in the next twelve months. Barclays PLC has the lowest price target set, forecasting a price of $95.00 for Ipsen in the next year.
View the latest price targets for IPSEY.

What is the current consensus analyst rating for Ipsen?

Ipsen currently has 3 sell ratings, 6 hold ratings and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in IPSEY, but not buy more shares or sell existing shares.
View the latest ratings for IPSEY.

What other companies compete with Ipsen?

How do I contact Ipsen's investor relations team?

Ipsen's physical mailing address is 65 quai Georges Gorse, Boulogne-Billancourt cedex I0, 92650. The company's listed phone number is (315) 833-5000 and its investor relations email address is [email protected] The official website for Ipsen is www.ipsen.com. Learn More about contacing Ipsen investor relations.